findmyKOL

Lejla Vajzovic, MD

Enriched profile

Professor of Ophthalmology · Duke University School of Medicine

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Durham, NC · Southeast · United StatesSpecialtyOphthalmologyFocusRetinal Diseases and Treatments+4
Active KOLfindmyKOL type: EliteLatest publication2024Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Lejla Vajzovic is Professor of Ophthalmology at Duke University School of Medicine. OpenAlex indexes 215 publications with 2,892 citations (h-index 28); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.

Data verified 16 Oct 2026

Overview

Updated 16 Oct 2026

Lejla Vajzovic, M.D., is Professor of Ophthalmology at Duke University School of Medicine, Department of Ophthalmology. The public record shows 215 publications with 2,892 citations (h-index 28), centered on Retinal Diseases and Treatments, Retinal Imaging and Analysis, Optical Coherence Tomography Applications. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 28 companies.

  • Most recent indexed publication: 2024 · Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • Top research focus: Retinal Diseases and Treatments
  • 4 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 28 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Retinal Detachment1 trialRetinal Telangiectasis1 trialRetinopathy of Prematurity1 trialGlaucoma1 trialComa1 trialOptic Nerve Diseases1 trialMacular Degeneration (AMD)

Research focus

OpenAlex concept fingerprint
Retinal Diseases and TreatmentsRetinal Imaging and AnalysisOptical Coherence Tomography ApplicationsRetinal and Macular SurgeryRetinal Development and Disorders

Drugs & molecules

across trials, industry payments and publications
Beovugeneric · BrolucizumabClinical trials—Industry payments2Publications1Ozurdexgeneric · DexamethasoneClinical trials—Industry payments68Publications—Syfovregeneric · PegcetacoplanClinical trials—Industry payments23Publications—Vabysmogeneric · FaricimabClinical trials—Industry payments15Publications—Izervaygeneric · Avacincaptad pegolClinical trials—Industry payments13Publications—Xiperegeneric · TriamcinoloneClinical trials—Industry payments13Publications—Lucentisgeneric · RanibizumabClinical trials—Industry payments11Publications—Retisertgeneric · FluocinoloneClinical trials—Industry payments11Publications—EYLEA HDClinical trials—Industry payments6Publications—VorolanibClinical trials—Industry payments6Publications—Eyleageneric · AfliberceptClinical trials—Industry payments5Publications—Brilliant blue GClinical trials—Industry payments4Publications—

Works with

trial sponsors and companies reporting payments
Alcon Vision LLCClinical trials—Industry payments91Abbvie Inc.Clinical trials—Industry payments67Apellis Pharmaceuticals, Inc.Clinical trials—Industry payments51Bausch & Lomb Americas Inc.Clinical trials—Industry payments32Ocular Therapeutix, Inc.Clinical trials—Industry payments32Alcon Research LLCClinical trials—Industry payments24Genentech USA, Inc.Clinical trials—Industry payments20Astellas Pharma US IncClinical trials—Industry payments18EyePoint Pharmaceuticals US, Inc.Clinical trials—Industry payments10Astellas Pharma Global DevelopmentClinical trials—Industry payments6Dutch Ophthalmic, USAClinical trials—Industry payments6Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments6Oculus Surgical Inc.Clinical trials—Industry payments5Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments5Allergan, Inc.Clinical trials—Industry payments4Genentech, Inc.Clinical trials—Industry payments4Alimera Sciences, Inc.Clinical trials—Industry payments3Novartis Pharmaceuticals CorporationClinical trials—Industry payments3Bausch & Lomb, a division of Bausch Health US, LLCClinical trials—Industry payments2Coherus Biosciences Inc.Clinical trials—Industry payments2Duke UniversityClinical trials2Industry payments—F. Hoffmann-La Roche AGClinical trials—Industry payments2Heidelberg Engineering, Inc.Clinical trials—Industry payments2ANI Pharmaceuticals, Inc.Clinical trials—Industry payments1Beaver-Visitec International, Inc.Clinical trials—Industry payments1BioCryst Pharmaceuticals, Inc.Clinical trials—Industry payments1Heidelberg Engineering GmbHClinical trials1Industry payments—Lejla Vajzovic, MD, FASRSClinical trials1Industry payments—Neurotech Pharmaceuticals, Inc.Clinical trials—Industry payments1Sumitomo Pharma Co., Ltd.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
215publications

Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.

2,892citations

Total citations across indexed works.

28h-index

Hirsch index (OpenAlex). i10-index 60.

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials ↓
28companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 16 Oct 2026

28 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    94.6%
    Antineovascularisation agents91.2%
    Faricimab-svoa100%
    Part B, office-administered≥20 patients
    Corticosteroid1.6%
    Prednisolone Acetate100%
    Part D≥48 patients

    + 4 more classes in this area

  • Cancer & immunology

    4%
    Vascular Endothelial Growth Factor Inhibitor4%
    Aflibercept83%Bevacizumab17%
    Part B, office-administered≥24 patients
  • Musculoskeletal

    1.2%
    Cyclooxygenase Inhibitor1.2%
    Ketorolac Tromethamine100%
    Part D≥37 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)2.6% facility · 97.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 16 Oct 2026

2 congress contributions (2012–2014) across ASTRO per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Cynthia Ann Toth87Joseph A. Izatt41Christian Viehland37S. Tammy Hsu27Sandra S. Stinnett26Prithvi Mruthyunjaya25Sharon F. Freedman22Shwetha Mangalesh18Avni P. Finn18Du Tran-Viet18Anthony N. Kuo16Al-Hafeez Z. Dhalla15Neeru Sarin14Oscar M. Carrasco‐Zevallos14Jianwei D. Li13Xi Chen13Sina Farsiu12Mays El-Dairi11Arathi Ponugoti11Hoan T. Ngo11Robert M. Trout10Sally Shin Yee Ong10Michael P. Kelly10Dilraj Singh Grewal9Sasapin Grace Prakalapakorn9Charles Michael Cotten9Gui‐Shuang Ying9Alexandria Dandridge9Wenlan Zhang9Hesham Gabr9Katrina Postell Winter8Brendan McGeehan8Amit M. Narawane8Vincent Tai8Liangbo Linus Shen8Caroline R. Baumal8Glenn J. Jaffe8Mohsin H. Ali8Akshay S. Thomas7Sharon Fekrat7

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/lejla-vajzovic-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/lejla-vajzovic-md-fasrs-493841188

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • Other

    aminer.org/profile/lejla-vajzovik/617927c86750f81e1c9670df

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aminer.org ↗

Mentions by others

where others cite or feature them
  • Other

    ophthalmologytimes.com/authors/lejla-vajzovic-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ophthalmologytimes.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.D.

    Mayo Clinic Alix School of Medicine

    2006
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
  • B.S.

    University of Missouri, Columbia

    2002
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Duke Eye Center

    Vitreoretinal Diseases & Surgery division

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
  • Director

    Duke Center for Artificial and Regenerative Vision

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
  • Co-director

    Duke Pediatric Retina and Optic Nerve Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.